Loading...
XASX1AI
Market cap7mUSD
Dec 23, Last price  
0.02AUD
Name

Living Cell Technologies Ltd

Chart & Performance

D1W1MN
XASX:1AI chart
P/E
—
P/S
197.58
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
22.39%
Rev. gr., 5y
66.55%
Revenues
125k
+197.98%
65,4121,30718,29251,946186,463517,087176,5383,708,0007,580,0007,394,130611,955120,091115,279121,4039,7693,168268,1843,40542,016125,200
Net income
-2m
L-0.57%
0-6,819,611-5,987,322-6,794,037-6,123,562-5,674,059-6,795,7085,676,000-2,979,000-6,778,896-7,043,402-3,093,163-4,090,257-374,492-3,181,363-968,469-1,460,591-1,957,300-2,107,658-2,095,562
CFO
-2m
L-23.31%
-6,094,932-6,610,850-5,536,559-5,598,158-5,703,572-5,863,818-5,723,151-2,487,0001,337,000-82,441-3,587,334-3,157,129-3,370,078-3,570,306-1,990,530-3,109,785-1,461,523-2,042,204-1,986,291-1,523,301
Earnings
Feb 26, 2025

Profile

Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in Australia and New Zealand. It is developing NTCELL, an alginate-coated capsule, which is in phase IIb clinical trial for the treatment of Parkinson's disease. The company was founded in 1987 and is based in Sydney, Australia.
URL
https://lctglobal.com/
IPO date
Sep 01, 2004
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
125
197.98%
42
1,133.95%
3
-98.73%
Cost of revenue
1,705
1,310
1,464
Unusual Expense (Income)
NOPBT
(1,580)
(1,268)
(1,460)
NOPBT Margin
Operating Taxes
3
(415)
Tax Rate
NOPAT
(1,580)
(1,268)
(1,046)
Net income
(2,096)
-0.57%
(2,108)
7.68%
(1,957)
34.01%
Dividends
Dividend yield
Proceeds from repurchase of equity
572
2,149
2,857
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(3,108)
(4,111)
(4,239)
Cash flow
Cash from operating activities
(1,523)
(1,986)
(2,042)
CAPEX
(4)
Cash from investing activities
(277)
39
Cash from financing activities
523
1,850
4,686
FCF
(1,575)
(1,268)
(1,035)
Balance
Cash
3,108
4,111
4,239
Long term investments
Excess cash
3,102
4,109
4,239
Stockholders' equity
3,014
3,762
4,035
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
1,663,114
1,346,990
886,621
Price
Market cap
EV
EBITDA
(1,580)
(1,268)
(1,460)
EV/EBITDA
Interest
Interest/NOPBT